Prostate Cancer Trials Face Randomization Challenges In U.S.
This article was originally published in The Gray Sheet
Executive Summary
Device marketing, patient preferences, physician bias and financial incentives can thwart attempts by comparative effectiveness researchers to randomize prostate cancer patients into clinical trials.
You may also be interested in...
Advisory Panel Urges Randomized Trials For New Prostate Cancer Treatments
Developers of targeted prostate cancer treatments should conduct randomized clinical trials with "watchful waiting" as a control, according to FDA's Gastroenterology and Urology Devices panel
Institute Of Medicine Sets Top 100 Comparative Effectiveness Priorities
A June 30 Institute of Medicine 1report to Congress includes dozens of surgical- and device-related topics among a list of 100 recommended priorities for federally-funded comparative effectiveness research
Debate Stirs Over Medicare Coverage For Proton Therapy In Prostate Cancer
A private insurer is calling for CMS to issue a national non-coverage decision for proton therapy in treating prostate cancer, claiming Medicare payments will encourage rapid spread of the costly technology before there is enough clinical evidence to deem the treatment reasonable and necessary